Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis
Open Access
- 30 August 2011
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 63 (12), 3692-3701
- https://doi.org/10.1002/art.30599
Abstract
Objective To examine blood B cell subsets in patients with rheumatoid arthritis (RA) prior to B cell depletion therapy and to assess their potential as predictors of clinical response to rituximab (RTX). Methods Blood B cell subsets were assessed by flow cytometry in 208 RA patients included in an RTX retreatment study (assessed prior to RTX treatment) and in 47 age‐matched controls. Expression of BAFF receptor (BAFF‐R) on B cells and serum B cell biomarkers was also measured. B cell subsets and BAFF‐R expression were compared between RA patient and control populations. Univariate and multivariate analyses were performed to identify baseline factors associated with a European League Against Rheumatism response 24 weeks after 1 cycle of RTX. Results Mean ± SD counts of both CD27− naive and CD27+ memory B cells were decreased in RA patients (188.6 ± 121.4/mm3) compared with controls (257.3 ± 154.1/mm3) (P = 0.001) and were partially restored in patients treated with methotrexate (MTX) plus anti–tumor necrosis factor compared with patients treated with MTX alone. Within the CD27+ memory B cells, the CD27+IgD− switched memory subtype was selectively decreased, irrespective of treatment. The frequency of CD27+ memory B cells correlated inversely with levels of several B cell activation biomarkers in RA. Serum BAFF level and BAFF‐R expression was comparable in RA patients and controls. A low baseline CD27+ memory B cell frequency was associated with a greater clinical response to RTX (odds ratio 0.97 [95% confidence interval 0.95–0.99], P = 0.0015). Conclusion In B cell depletion therapy–naive RA patients, a low frequency of CD27+ memory B cells correlated with levels of serum B cell activation biomarkers and may predict response to RTX. These results suggest that low memory B cell frequency may be indicative of a B cell–driven RA subtype that is more sensitive to B cell depletion therapy.Keywords
This publication has 41 references indexed in Scilit:
- Management of nonresponse to rituximab in rheumatoid arthritis: Predictors and outcome of re‐treatmentArthritis & Rheumatism, 2010
- Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targetsImmunologic Research, 2009
- Rituximab: A new therapeutic alternative in rheumatoid arthritisJoint Bone Spine, 2008
- Anti‐CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatmentArthritis & Rheumatism, 2008
- Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosusAnnals Of The Rheumatic Diseases, 2007
- B cell depletion therapy in autoimmune diseasesFrontiers in Bioscience-Landmark, 2007
- Regeneration of B cell subsets after transient B cell depletion using anti‐CD20 antibodies in rheumatoid arthritisArthritis & Rheumatism, 2006
- Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosusArthritis & Rheumatism, 2004
- Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndromeArthritis & Rheumatism, 2004
- Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndromeArthritis & Rheumatism, 2002